Metabolic Reprogramming: A Crucial Contributor to Anticancer Drug Resistance

Abstract

Cancer metabolic reprogramming is a fundamental hallmark that enables tumor cells to sustain their malignant behaviors. Beyond its role in supporting growth, invasion, and migration, metabolic rewiring actively contributes to anticancer drug resistance. Cancer cells not only reshape their own metabolism but also engage in aberrant metabolic crosstalk with nonmalignant components within the tumor microenvironment (TME). These metabolic alterations create multiple barriers to the efficacy of drug therapies, including chemotherapy, targeted therapy, and immunotherapy. Despite growing evidence, an integrated understanding of how metabolic reprogramming contributes to the development of drug resistance and how it may be therapeutically targeted to overcome the resistance remains incomplete. This review summarizes recent progresses in tumor-intrinsic and TME-associated metabolic alterations that contribute to drug resistance by sustaining metabolic needs and modulating nonmetabolic processes and explores the upstream regulatory mechanisms driving these changes, focusing particularly on glucose, lipid, and amino acid metabolism. We also discuss the current advances in the integration of small molecule inhibitors targeting cancer metabolism to address drug resistance. By consolidating mechanistic insights and therapeutic opportunities, this review highlights metabolic reprogramming as a promising intervention point to overcome anticancer drug resistance.

Keywords

cancer metabolism / drug resistance / metabolic targeted strategies / tumor microenvironment

References

[1] L. W. S. Finley, “What Is Cancer Metabolism?,” Cell 186, no. 8 (2023): 1670-1688.

[2] I. Martínez-Reyes and N. S. Chandel, “Cancer Metabolism: Looking Forward,” Nature Reviews Cancer 21, no. 10 (2021): 669-680.

[3] M. Tufail, C. H. Jiang, and N. Li, “Altered Metabolism in Cancer: Insights Into Energy Pathways and Therapeutic Targets,” Molecular cancer 23, no. 1 (2024): 203.

[4] Y. Xiao, T. J. Yu, Y. Xu, et al., “Emerging Therapies in Cancer Metabolism,” Cell metabolism 35, no. 8 (2023): 1283-1303.

[5] G. Kroemer and J. Pouyssegur, “Tumor Cell Metabolism: Cancer's Achilles' heel,” Cancer Cell 13, no. 6 (2008): 472-482.

[6] J. D. Hayes, A. T. Dinkova-Kostova, and K. D. Tew, “Oxidative Stress in Cancer,” Cancer Cell 38, no. 2 (2020): 167-197.

[7] X. Chen, J. Li, R. Kang, D. J. Klionsky, and D. Tang, “Ferroptosis: Machinery and Regulation,” Autophagy 17, no. 9 (2021): 2054-2081.

[8] A. Bansal and M. C. Simon, “Glutathione Metabolism in Cancer Progression and Treatment Resistance,” Journal of Cell Biology 217, no. 7 (2018): 2291-2298.

[9] E. Pranzini, E. Pardella, P. Paoli, S. M. Fendt, and M. L. Taddei, “Metabolic Reprogramming in Anticancer Drug Resistance: A Focus on Amino Acids,” Trends in cancer 7, no. 8 (2021): 682-699.

[10] S. Sivanand and M. G. Vander Heiden, “Emerging Roles for Branched-Chain Amino Acid Metabolism in Cancer,” Cancer Cell 37, no. 2 (2020): 147-156.

[11] Z. Zhang, P. Yue, T. Lu, Y. Wang, Y. Wei, and X. Wei, “Role of Lysosomes in Physiological Activities, Diseases, and Therapy,” Journal of hematology & oncology 14, no. 1 (2021): 79.

[12] H. Joyce, A. McCann, M. Clynes, and A. Larkin, “Influence of Multidrug Resistance and Drug Transport Proteins on Chemotherapy Drug Metabolism,” Expert Opinion on Drug Metabolism & Toxicology 11, no. 5 (2015): 795-809.

[13] R. A. Ward, S. Fawell, N. Floc'h, V. Flemington, D. McKerrecher, and P. D. Smith, “Challenges and Opportunities in Cancer Drug Resistance,” Chem. Rev. 121, no. 6 (2021): 3297-3351.

[14] C. Holohan, S. Van Schaeybroeck, D. B. Longley, and P. G. Johnston, “Cancer Drug Resistance: An Evolving Paradigm,” Nature Reviews Cancer 13, no. 10 (2013): 714-726.

[15] M. Choo, V. H. Mai, H. S. Kim, et al., “Involvement of Cell Shape and Lipid Metabolism in Glioblastoma Resistance to Temozolomide,” Acta Pharmacologica Sinica 44, no. 3 (2023): 670-679.

[16] H. Muley, K. Valencia, J. Casas, et al., “Cpt1c Downregulation Causes Plasma Membrane Remodelling and Anthracycline Resistance in Breast Cancer,” International Journal of Molecular Sciences 24, no. 2 (2023), https://doi.org/10.3390/ijms24020946.

[17] Q. Dong, C. Zhou, H. Ren, et al., “Lactate-induced MRP1 Expression Contributes to Metabolism-based Etoposide Resistance in Non-small Cell Lung Cancer Cells,” Cell Communication and Signaling 18, no. 1 (2020): 167.

[18] P. P. Liu, J. Liao, Z. J. Tang, et al., “Metabolic Regulation of Cancer Cell Side Population by Glucose Through Activation of the Akt Pathway,” Cell Death and Differentiation 21, no. 1 (2014): 124-135.

[19] P. Alarcon-Zapata, A. J. Perez, K. Toledo-Oñate, et al., “Metabolomics Profiling and Chemoresistance Mechanisms in Ovarian Cancer Cell Lines: Implications for Targeting Glutathione Pathway,” Life Sciences 333 (2023): 122166.

[20] J. Ebner, J. Schmoellerl, M. Piontek, et al., “ABCC1 and Glutathione Metabolism Limit the Efficacy of BCL-2 Inhibitors in Acute Myeloid Leukemia,” Nature Communications 14, no. 1 (2023): 5709.

[21] L. Al-Akra, D. H. Bae, S. Sahni, et al., “Tumor Stressors Induce Two Mechanisms of Intracellular P-glycoprotein-mediated Resistance That Are Overcome by Lysosomal-targeted Thiosemicarbazones,” Journal of Biological Chemistry 293, no. 10 (2018): 3562-3587.

[22] Y. J. Li, J. F. Fahrmann, M. Aftabizadeh, et al., “Fatty Acid Oxidation Protects Cancer Cells From Apoptosis by Increasing Mitochondrial Membrane Lipids,” Cell reports 39, no. 9 (2022): 110870.

[23] J. Zhang, M. Y. Ali, H. B. Chong, et al., “Oxidation of Retromer Complex Controls Mitochondrial Translation,” Nature 641 (2025): 1048-1058.

[24] N. Zhou, J. Chen, Z. Ling, et al., “Aryl Hydrocarbon Receptor Sulfenylation Promotes Glycogenolysis and Rescues Cancer Chemoresistance,” Journal of Clinical Investigation 133, no. 24 (2023): e170753.

[25] Y. Wang, J. Zhang, S. Ren, et al., “Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors,” Cell reports 28, no. 2 (2019): 512-525.e6.

[26] Q. You, J. Wang, Y. Yu, et al., “The Histone Deacetylase SIRT6 Promotes Glycolysis Through the HIF-1α/HK2 Signaling Axis and Induces Erlotinib Resistance in Non-small Cell Lung Cancer,” Apoptosis 27, no. 11-12 (2022): 883-898.

[27] J. G. Pastorino, N. Shulga, and J. B. Hoek, “Mitochondrial Binding of Hexokinase II Inhibits Bax-induced Cytochrome c Release and Apoptosis,” Journal of Biological Chemistry 277, no. 9 (2002): 7610-7618.

[28] Y. Zhou, H. Zhao, R. Ren, et al., “GPAT3 is a Potential Therapeutic Target to Overcome Sorafenib Resistance in Hepatocellular Carcinoma,” Theranostics 14, no. 9 (2024): 3470-3485.

[29] K. Zeng, W. Li, Y. Wang, et al., “Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4-mediated Ferroptosis in Colorectal Cancer,” Adv Sci (Weinh) 10, no. 25 (2023): e2301088.

[30] H. Zhang, M. Wang, Y. He, et al., “Chemotoxicity-induced Exosomal lncFERO Regulates Ferroptosis and Stemness in Gastric Cancer Stem Cells,” Cell death & disease 12, no. 12 (2021): 1116.

[31] H. Lee, A. Horbath, L. Kondiparthi, et al., “Cell Cycle Arrest Induces Lipid Droplet Formation and Confers Ferroptosis Resistance,” Nature Communications 15, no. 1 (2024): 79.

[32] H. Zhu, Q. Liu, Q. Meng, et al., “CCT3/ACTN4/TFRC Axis Protects Hepatocellular Carcinoma Cells From Ferroptosis by Inhibiting Iron Endocytosis,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 245.

[33] G. Lei, C. Mao, A. D. Horbath, et al., “BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers,” Cancer discovery 14, no. 8 (2024): 1476-1495.

[34] Z. Zhu, H. Shen, J. Xu, et al., “GATA3 mediates Doxorubicin Resistance by Inhibiting CYB5R2-catalyzed Iron Reduction in Breast Cancer Cells,” Drug Resistance Updates 69 (2023): 100974.

[35] F. Cheng, J. Dou, Y. Yang, et al., “Drug-induced Lactate Confers Ferroptosis Resistance via p38-SGK1-NEDD4L-dependent Upregulation of GPX4 in NSCLC Cells,” Cell Death Discov 9, no. 1 (2023): 165.

[36] S. Ouyang, H. Li, L. Lou, et al., “Inhibition of STAT3-ferroptosis Negative Regulatory Axis Suppresses Tumor Growth and Alleviates Chemoresistance in Gastric Cancer,” Redox Biology 52 (2022): 102317.

[37] Z. Xu, X. Wang, W. Sun, et al., “RelB-activated GPX4 Inhibits Ferroptosis and Confers Tamoxifen Resistance in Breast Cancer,” Redox Biology 68 (2023): 102952.

[38] C. Zeng, D. Nie, X. Wang, et al., “Combined Targeting of GPX4 and BCR-ABL Tyrosine Kinase Selectively Compromises BCR-ABL+ Leukemia Stem Cells,” Molecular cancer 23, no. 1 (2024): 240.

[39] J. Deng, X. Lin, J. Qin, et al., “SPTBN2 suppresses Ferroptosis in NSCLC Cells by Facilitating SLC7A11 Membrane Trafficking and Localization,” Redox Biology 70 (2024): 103039.

[40] J. Tang, G. Long, D. Xiao, et al., “ATR-dependent Ubiquitin-specific Protease 20 Phosphorylation Confers Oxaliplatin and Ferroptosis Resistance,” MedComm 4, no. 6 (2023): e463.

[41] J. Y. Yang, X. Y. Lei, K. Y. He, et al., “HMGA1 drives Chemoresistance in Esophageal Squamous Cell Carcinoma by Suppressing Ferroptosis,” Cell death & disease 15, no. 2 ( 2024): 158.

[42] Q. Zhang, N. Li, L. Deng, et al., “ACSL1-induced Ferroptosis and Platinum Resistance in Ovarian Cancer by Increasing FSP1 N-myristylation and Stability,” Cell Death Discov 9, no. 1 (2023): 83.

[43] M. Zhan, Y. Ding, S. Huang, et al., “Lysyl Oxidase-Like 3 Restrains Mitochondrial Ferroptosis to Promote Liver Cancer Chemoresistance by Stabilizing Dihydroorotate Dehydrogenase,” Nature Communications 14, no. 1 (2023): 3123.

[44] Z. Miao, L. Xu, W. Gu, et al., “A Targetable PRR11-DHODH Axis Drives Ferroptosis- and Temozolomide-resistance in Glioblastoma,” Redox Biology 73 (2024): 103220.

[45] L. Han, L. Meng, J. Liu, et al., “Macroautophagy/Autophagy Promotes Resistance to KRAS(G12D)-targeted Therapy Through Glutathione Synthesis,” Cancer Letters 604 (2024): 217258.

[46] L. Yang, C. Fang, J. Han, et al., “CKS2 induces Autophagy-mediated Glutathione Metabolic Reprogramming to Facilitate Ferroptosis Resistance in Colon Cancer,” Molecular Medicine 30, no. 1 (2024): 219.

[47] S. Díaz-Gago, J. Vicente-Gutiérrez, and J. M. Ruiz-Rodríguez, “Autophagy Sustains Mitochondrial Respiration and Determines Resistance to BRAF(V600E) Inhibition in Thyroid Carcinoma Cells,” Autophagy 20, no. 6 (2024): 1383-1397.

[48] D. Lu, Y. Li, X. Niu, et al., “STAT2/SLC27A3/PINK1-Mediated Mitophagy Remodeling Lipid Metabolism Contributes to Pazopanib Resistance in Clear Cell Renal Cell Carcinoma,” Research (Wash D C) 7 (2024): 0539.

[49] W. Li, C. Zhou, L. Yu, et al., “Tumor-derived Lactate Promotes Resistance to Bevacizumab Treatment by Facilitating Autophagy Enhancer Protein RUBCNL Expression Through Histone H3 Lysine 18 Lactylation (H3K18la) in Colorectal Cancer,” Autophagy 20, no. 1 (2024): 114-130.

[50] J. Yang, H. Wang, B. Li, et al., “Inhibition of ACSS2 Triggers Glycolysis Inhibition and Nuclear Translocation to Activate SIRT1/ATG5/ATG2B Deacetylation Axis, Promoting Autophagy and Reducing Malignancy and Chemoresistance in Ovarian Cancer,” Metabolism 162 (2025): 156041.

[51] L. Luo, W. Sun, W. Zhu, et al., “BCAT1 decreases the Sensitivity of Cancer Cells to Cisplatin by Regulating mTOR-mediated Autophagy via Branched-chain Amino Acid Metabolism,” Cell death & disease 12, no. 2 (2021): 169.

[52] Z. Xing, X. Jiang, Y. Chen, et al., “Glutamine Deprivation in Glioblastoma Stem Cells Triggers Autophagic SIRT3 Degradation to Epigenetically Restrict CD133 Expression and Stemness,” Apoptosis 29, no. 9-10 (2024): 1619-1631.

[53] W. Hu, X. Cui, H. Liu, et al., “CYP3A5 promotes Glioblastoma Stemness and Chemoresistance Through Fine-tuning NAD(+)/NADH Ratio,” Journal of Experimental & Clinical Cancer Research 44, no. 1 (2025): 3.

[54] A. Güldenpfennig, A. K. Hopp, L. Muskalla, et al., “Absence of Mitochondrial SLC25A51 Enhances PARP1-dependent DNA Repair by Increasing Nuclear NAD+ Levels,” Nucleic Acids Res. 51, no. 17 (2023): 9248-9265.

[55] B. Lu, S. Chen, X. Guan, et al., “Lactate Accumulation Induces H4K12la to Activate Super-enhancer-driven RAD23A Expression and Promote Niraparib Resistance in Ovarian Cancer,” Molecular cancer 24, no. 1 (2025): 83.

[56] Y. Chen, J. Wu, L. Zhai, et al., “Metabolic Regulation of Homologous Recombination Repair by MRE11 Lactylation,” Cell 187, no. 2 (2024): 294-311.e21.

[57] H. Chen, Y. Li, H. Li, et al., “NBS1 lactylation Is Required for Efficient DNA Repair and Chemotherapy Resistance,” Nature 631, no. 8021 (2024): 663-669.

[58] K. Shigeta, M. Hasegawa, T. Hishiki, et al., “IDH2 stabilizes HIF-1α-induced Metabolic Reprogramming and Promotes Chemoresistance in Urothelial Cancer,” Embo Journal 42, no. 4 (2023): e110620.

[59] J. Liu, H. Wang, H. Wan, et al., “NEK6 dampens FOXO3 Nuclear Translocation to Stabilize C-MYC and Promotes Subsequent De Novo Purine Synthesis to Support Ovarian Cancer Chemoresistance,” Cell death & disease 15, no. 9 (2024): 661.

[60] E. Pranzini, E. Pardella, L. Muccillo, et al., “SHMT2-mediated Mitochondrial Serine Metabolism Drives 5-FU Resistance by Fueling Nucleotide Biosynthesis,” Cell reports 40, no. 7 (2022): 111233.

[61] Z. Chen, J. Xu, K. Fang, et al., “FOXC1-mediated Serine Metabolism Reprogramming Enhances Colorectal Cancer Growth and 5-FU Resistance Under Serine Restriction,” Cell Communication and Signaling 23, no. 1 (2025): 13.

[62] S. Zou, B. Qin, Z. Yang, et al., “CSN6 Mediates Nucleotide Metabolism to Promote Tumor Development and Chemoresistance in Colorectal Cancer,” Cancer Research 83, no. 3 (2023): 414-427.

[63] K. Ganguly, R. Bhatia, S. Rauth, et al., “Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency during Pancreatic Cancer Chemoresistance,” Gastroenterology 162, no. 1 (2022): 253-268.e13.

[64] Q. Li, T. Qin, Z. Bi, et al., “Rac1 activates Non-oxidative Pentose Phosphate Pathway to Induce Chemoresistance of Breast Cancer,” Nature Communications 11, no. 1 ( 2020): 1456.

[65] F. Li, H. Zhang, Y. Huang, et al., “Single-cell Transcriptome Analysis Reveals the Association Between Histone Lactylation and Cisplatin Resistance in Bladder Cancer,” Drug Resistance Updates 73 (2024): 101059.

[66] J. I. Fletcher, R. T. Williams, M. J. Henderson, M. D. Norris, and M. Haber, “ABC Transporters as Mediators of Drug Resistance and Contributors to Cancer Cell Biology,” Drug Resistance Updates 26 (2016): 1-9.

[67] M. Kartal-Yandim, A. Adan-Gokbulut, and Y. Baran, “Molecular Mechanisms of Drug Resistance and Its Reversal in Cancer,” Critical Reviews in Biotechnology 36, no. 4 (2016): 716-726.

[68] X. Wen, B. Buckley, E. McCandlish, et al., “Transgenic Expression of the human MRP2 Transporter Reduces Cisplatin Accumulation and Nephrotoxicity in Mrp2-null Mice,” American Journal of Pathology 184, no. 5 (2014): 1299-1308.

[69] R. Oun, Y. E. Moussa, and N. J. Wheate, “The Side Effects of Platinum-based Chemotherapy Drugs: A Review for Chemists,” Dalton Transactions 47, no. 19 (2018): 6645-6653.

[70] C. Settembre and R. M. Perera, “Lysosomes as Coordinators of Cellular Catabolism, Metabolic Signalling and Organ Physiology,” Nature Reviews Molecular Cell Biology 25, no. 3 (2024): 223-245.

[71] B. Niu, K. Liao, Y. Zhou, et al., “Application of Glutathione Depletion in Cancer Therapy: Enhanced ROS-based Therapy, Ferroptosis, and Chemotherapy,” Biomaterials 277 (2021): 121110.

[72] E. C. Cheung and K. H. Vousden, “The Role of ROS in Tumour Development and Progression,” Nature Reviews Cancer 22, no. 5 (2022): 280-297.

[73] S. H. Kaufmann and W. C. Earnshaw, “Induction of Apoptosis by Cancer Chemotherapy,” Experimental Cell Research 256, no. 1 (2000): 42-49.

[74] V. E. Kagan, V. A. Tyurin, J. Jiang, et al., “Cytochrome c Acts as a Cardiolipin Oxygenase Required for Release of Proapoptotic Factors,” Nature Chemical Biology 1, no. 4 (2005): 223-232.

[75] H. R. Stennicke, Q. L. Deveraux, E. W. Humke, J. C. Reed, V. M. Dixit, and G. S. Salvesen, “Caspase-9 Can be Activated Without Proteolytic Processing,” Journal of Biological Chemistry 274, no. 13 (1999): 8359-8362.

[76] X. Jiang, B. R. Stockwell, and M. Conrad, “Ferroptosis: Mechanisms, Biology and Role in Disease,” Nature Reviews Molecular Cell Biology 22, no. 4 (2021): 266-282.

[77] C. Chen, Y. Yang, Y. Guo, et al., “CYP1B1 inhibits Ferroptosis and Induces Anti-PD-1 Resistance by Degrading ACSL4 in Colorectal Cancer,” Cell death & disease 14, no. 4 (2023): 271.

[78] Y. Wang, X. Wu, Z. Ren, et al., “Overcoming Cancer Chemotherapy Resistance by the Induction of Ferroptosis,” Drug Resistance Updates 66 (2023): 100916.

[79] H. F. Yan, T. Zou, Q. Z. Tuo, et al., “Ferroptosis: Mechanisms and Links With Diseases,” Signal Transduct Target Ther 6, no. 1 (2021): 49.

[80] Y. Lu, Y. T. Chan, H. Y. Tan, et al., “Epigenetic Regulation of Ferroptosis via ETS1/miR-23a-3p/ACSL4 Axis Mediates Sorafenib Resistance in human Hepatocellular Carcinoma,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 3.

[81] L. Ma, C. Chen, C. Zhao, et al., “Targeting Carnitine Palmitoyl Transferase 1A (CPT1A) Induces Ferroptosis and Synergizes With Immunotherapy in Lung Cancer,” Signal Transduct Target Ther 9, no. 1 (2024): 64.

[82] S. J. Dixon, G. E. Winter, L. S. Musavi, et al., “Human Haploid Cell Genetics Reveals Roles for Lipid Metabolism Genes in Nonapoptotic Cell Death,” Acs Chemical Biology 10, no. 7 (2015): 1604-1609.

[83] C. C. Winterbourn, “Toxicity of Iron and Hydrogen Peroxide: The Fenton Reaction,” Toxicology Letters 82-83 (1995): 969-974.

[84] M. S. Mortensen, J. Ruiz, and J. L. Watts, “Polyunsaturated Fatty Acids Drive Lipid Peroxidation During Ferroptosis,” Cells 12, no. 5 (2023): 804.

[85] Z. Li, Y. Hu, H. Zheng, et al., “LPCAT1-mediated Membrane Phospholipid Remodelling Promotes Ferroptosis Evasion and Tumour Growth,” Nature Cell Biology 26, no. 5 (2024): 811-824.

[86] C. M. Paton and J. M. Ntambi, “Biochemical and Physiological Function of Stearoyl-CoA Desaturase,” American Journal of Physiology. Endocrinology and Metabolism 297, no. 1 (2009): E28-37.

[87] J. M. Ntambi and M. Miyazaki, “Regulation of Stearoyl-CoA Desaturases and Role in Metabolism,” Progress in Lipid Research 43, no. 2 (2004): 91-104.

[88] G. Luis, A. Godfroid, S. Nishiumi, et al., “Tumor Resistance to Ferroptosis Driven by Stearoyl-CoA Desaturase-1 (SCD1) in Cancer Cells and Fatty Acid Biding Protein-4 (FABP4) in Tumor Microenvironment Promote Tumor Recurrence,” Redox Biology 43 (2021): 102006.

[89] G. Shan, G. Bi, G. Zhao, et al., “Inhibition of PKA/CREB1 Pathway Confers Sensitivity to Ferroptosis in Non-small Cell Lung Cancer,” Respiratory Research 24, no. 1 (2023): 277.

[90] L. Zhang, X. M. Li, X. H. Shi, et al., “Sorafenib Triggers Ferroptosis via Inhibition of HBXIP/SCD Axis in Hepatocellular Carcinoma,” Acta Pharmacologica Sinica 44, no. 3 (2023): 622-634.

[91] T. M. Seibt, B. Proneth, and M. Conrad, “Role of GPX4 in Ferroptosis and Its Pharmacological Implication,” Free Radic Biol Med 133 (2019): 144-152.

[92] S. Doll, F. P. Freitas, R. Shah, et al., “FSP1 is a Glutathione-independent Ferroptosis Suppressor,” Nature 575, no. 7784 (2019): 693-698.

[93] K. Bersuker, J. M. Hendricks, Z. Li, et al., “The CoQ Oxidoreductase FSP1 Acts Parallel to GPX4 to Inhibit Ferroptosis,” Nature 575, no. 7784 (2019): 688-692.

[94] C. Mao, X. Liu, Y. Zhang, et al., “DHODH-mediated Ferroptosis Defence Is a Targetable Vulnerability in Cancer,” Nature 593, no. 7860 (2021): 586-590.

[95] V. A. N. Kraft, C. T. Bezjian, S. Pfeiffer, et al., “GTP Cyclohydrolase 1/Tetrahydrobiopterin Counteract Ferroptosis Through Lipid Remodeling,” ACS Cent Sci 6, no. 1 ( 2020): 41-53.

[96] M. Soula, R. A. Weber, O. Zilka, et al., “Metabolic Determinants of Cancer Cell Sensitivity to Canonical Ferroptosis Inducers,” Nature Chemical Biology 16, no. 12 (2020): 1351-1360.

[97] K. Yamamoto, D. Iwadate, H. Kato, Y. Nakai, K. Tateishi, and M. Fujishiro, “Targeting Autophagy as a Therapeutic Strategy Against Pancreatic Cancer,” Journal of Gastroenterology 57, no. 9 (2022): 603-618.

[98] L. B. Pontel, A. Bueno-Costa, A. E. Morellato, J. Carvalho Santos, G. Roué, and M. Esteller, “Acute Lymphoblastic Leukemia Necessitates GSH-dependent Ferroptosis Defenses to Overcome FSP1-epigenetic Silencing,” Redox Biology 55 (2022): 102408.

[99] G. Lei, L. Zhuang, and B. Gan, “The Roles of Ferroptosis in Cancer: Tumor Suppression, Tumor Microenvironment, and Therapeutic Interventions,” Cancer Cell 42, no. 4 ( 2024): 513-534.

[100] Z. Yang, W. Su, X. Wei, et al., “HIF-1α Drives Resistance to Ferroptosis in Solid Tumors by Promoting Lactate Production and Activating SLC1A1,” Cell reports 42, no. 8 (2023): 112945.

[101] M. Hayano, W. S. Yang, C. K. Corn, N. C. Pagano, and B. R. Stockwell, “Loss of Cysteinyl-tRNA Synthetase (CARS) Induces the Transsulfuration Pathway and Inhibits Ferroptosis Induced by Cystine Deprivation,” Cell Death and Differentiation 23, no. 2 (2016): 270-278.

[102] J. Liu, Y. Wu, S. Meng, et al., “Selective Autophagy in Cancer: Mechanisms, Therapeutic Implications, and Future Perspectives,” Molecular cancer 23, no. 1 (2024): 22.

[103] L. Poillet-Perez, J. E. Sarry, and C. Joffre, “Autophagy Is a Major Metabolic Regulator Involved in Cancer Therapy Resistance,” Cell reports 36, no. 7 (2021): 109528.

[104] X. Niu, Q. You, K. Hou, et al., “Autophagy in Cancer Development, Immune Evasion, and Drug Resistance,” Drug Resistance Updates 78 (2025): 101170.

[105] D. Corallo, F. Pastorino, M. Pantile, et al., “Autophagic Flux Inhibition Enhances Cytotoxicity of the Receptor Tyrosine Kinase Inhibitor ponatinib,” Journal of Experimental & Clinical Cancer Research 39, no. 1 (2020): 195.

[106] E. White, “The Role for Autophagy in Cancer,” Journal of Clinical Investigation 125, no. 1 (2015): 42-46.

[107] J. D. Rabinowitz and E. White, “Autophagy and Metabolism,” Science 330, no. 6009 (2010): 1344-1348.

[108] C. Zhang, Z. Du, Y. Gao, et al., “Methionine Secreted by Tumor-associated Pericytes Supports Cancer Stem Cells in Clear Cell Renal Carcinoma,” Cell metabolism 36, no. 4 ( 2024): 778-792.e10.

[109] C. D. Gonzalez, S. Alvarez, A. Ropolo, C. Rosenzvit, M. F. Bagnes, and M. I. Vaccaro, “Autophagy, Warburg, and Warburg Reverse Effects in human Cancer,” BioMed research international 2014 (2014): 926729.

[110] D. Liu, H. Zhu, L. Cheng, et al., “Hypoxia-induced Galectin-8 Maintains Stemness in Glioma Stem Cells via Autophagy Regulation,” Neuro-oncol 26, no. 5 (2024): 872-888.

[111] F. J. Groelly, M. Fawkes, R. A. Dagg, A. N. Blackford, and M. Tarsounas, “Targeting DNA Damage Response Pathways in Cancer,” Nature Reviews Cancer 23, no. 2 (2023): 78-94.

[112] T. Sobanski, M. Rose, A. Suraweera, K. O'Byrne, D. J. Richard, and E. Bolderson, “Cell Metabolism and DNA Repair Pathways: Implications for Cancer Therapy,” Frontiers in Cell and Developmental Biology 9 (2021): 633305.

[113] R. Huang and P. K. Zhou, “DNA Damage Repair: Historical Perspectives, Mechanistic Pathways and Clinical Translation for Targeted Cancer Therapy,” Signal Transduct Target Ther 6, no. 1 (2021): 254.

[114] A. Ray Chaudhuri and A. Nussenzweig, “The Multifaceted Roles of PARP1 in DNA Repair and Chromatin Remodelling,” Nature Reviews Molecular Cell Biology 18, no. 10 ( 2017): 610-621.

[115] S. Yang, S. Hwang, B. Kim, S. Shin, M. Kim, and S. M. Jeong, “Fatty Acid Oxidation Facilitates DNA Double-strand Break Repair by Promoting PARP1 Acetylation,” Cell death & disease 14, no. 7 (2023): 435.

[116] J. Zhang, F. Chen, Y. Tian, et al., “PARylated PDHE1α Generates Acetyl-CoA for Local Chromatin Acetylation and DNA Damage Repair,” Nature structural & molecular biology 30, no. 11 (2023): 1719-1734.

[117] K. Xiang, C. Kalthoff, C. Münch, V. Jendrossek, and J. Matschke, “Accumulation of Oncometabolite D-2-Hydroxyglutarate by SLC25A1 Inhibition: A Metabolic Strategy for Induction of HR-ness and Radiosensitivity,” Cell death & disease 13, no. 7 (2022): 641.

[118] P. L. Sulkowski, S. Oeck, J. Dow, et al., “Oncometabolites Suppress DNA Repair by Disrupting Local Chromatin Signalling,” Nature 582, no. 7813 (2020): 586-591.

[119] C. Zheng, H. Tan, G. Niu, et al., “ACAT1-Mediated ME2 Acetylation Drives Chemoresistance in Ovarian Cancer by Linking Glutaminolysis to Lactate Production,” Adv Sci (Weinh) 12, no. 14 (2025): e2416467.

[120] C. Das, S. Adhikari, A. Bhattacharya, et al., “Epigenetic-Metabolic Interplay in the DNA Damage Response and Therapeutic Resistance of Breast Cancer,” Cancer Research 83, no. 5 (2023): 657-666.

[121] D. B. Longley, D. P. Harkin, and P. G. Johnston, “5-fluorouracil: Mechanisms of Action and Clinical Strategies,” Nature Reviews Cancer 3, no. 5 (2003): 330-338.

[122] J. G. Cory and A. H. Cory, “Critical Roles of Glutamine as Nitrogen Donors in Purine and Pyrimidine Nucleotide Synthesis: Asparaginase Treatment in Childhood Acute Lymphoblastic Leukemia,” In Vivo (Athens, Greece) 20, no. 5 (2006): 587-589.

[123] C. Cosentino, D. Grieco, and V. Costanzo, “ATM Activates the Pentose Phosphate Pathway Promoting Anti-oxidant Defence and DNA Repair,” Embo Journal 30, no. 3 (2011): 546-555.

[124] M. A. Gregory, A. D'Alessandro, and F. Alvarez-Calderon, “ATM/G6PD-driven Redox Metabolism Promotes FLT3 Inhibitor Resistance in Acute Myeloid Leukemia,” Pnas 113, no. 43 (2016): E6669-e6678.

[125] W. Zhou, Z. Zhao, A. Lin, et al., “GTP Signaling Links Metabolism, DNA Repair, and Responses to Genotoxic Stress,” Cancer discovery 14, no. 1 (2024): 158-175.

[126] Á. Quintanal-Villalonga, J. M. Chan, H. A. Yu, et al., “Lineage Plasticity in Cancer: A Shared Pathway of Therapeutic Resistance,” Nature reviews Clinical oncology 17, no. 6 (2020): 360-371.

[127] A. Mehta and B. Z. Stanger, “Lineage Plasticity: The New Cancer Hallmark on the Block,” Cancer Research 84, no. 2 (2024): 184-191.

[128] R. He, C. Hu, Y. Yuan, et al., “Glycolysis Reprogramming in CAFs Promotes Oxaliplatin Resistance in Pancreatic Cancer Through circABCC4 Mediated PKM2 Nuclear Translocation,” Cell death & disease 16, no. 1 (2025): 126.

[129] M. T. Broz, E. Y. Ko, K. Ishaya, et al., “Metabolic Targeting of Cancer Associated Fibroblasts Overcomes T-cell Exclusion and Chemoresistance in Soft-tissue Sarcomas,” Nature Communications 15, no. 1 (2024): 2498.

[130] K. Zhang, L. Guo, X. Li, Y. Hu, and N. Luo, “Cancer-associated Fibroblasts Promote Doxorubicin Resistance in Triple-negative Breast Cancer Through Enhancing ZFP64 Histone Lactylation to Regulate Ferroptosis,” Journal of translational medicine 23, no. 1 (2025): 247.

[131] H. Neuwirt, J. Bouchal, G. Kharaishvili, et al., “Cancer-associated Fibroblasts Promote Prostate Tumor Growth and Progression Through Upregulation of Cholesterol and Steroid Biosynthesis,” Cell Communication and Signaling 18, no. 1 (2020): 11.

[132] J. Cai, L. Song, F. Zhang, et al., “Targeting SRSF10 Might Inhibit M2 Macrophage Polarization and Potentiate anti-PD-1 Therapy in Hepatocellular Carcinoma,” Cancer Commun (Lond) 44, no. 11 (2024): 1231-1260.

[133] W. Xu, B. Zhou, P. Wang, et al., “N6-methyladenosine Modification of 3'tRF-AlaAGC Impairs PD-1 Blockade Efficacy by Promoting Lactic Acid Accumulation in the Tumor Microenvironment of Gastric Carcinoma,” Drug Resistance Updates 79 (2025): 101197.

[134] Z. Liu, W. Liu, W. Wang, et al., “CPT1A-mediated Fatty Acid Oxidation Confers Cancer Cell Resistance to Immune-mediated Cytolytic Killing,” Pnas 120, no. 39 (2023): e2302878120.

[135] B. Wang, J. Pei, S. Xu, J. Liu, and J. Yu, “A Glutamine Tug-of-war Between Cancer and Immune Cells: Recent Advances in Unraveling the Ongoing Battle,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 74.

[136] L. F. Campesato, S. Budhu, J. Tchaicha, et al., “Blockade of the AHR Restricts a Treg-macrophage Suppressive Axis Induced by L-Kynurenine,” Nature Communications 11, no. 1 (2020): 4011.

[137] H. Mu, Q. Zhang, D. Zuo, et al., “Methionine Intervention Induces PD-L1 Expression to Enhance the Immune Checkpoint Therapy Response in MTAP-deleted Osteosarcoma,” Cell Rep Med 6, no. 3 (2025): 101977.

[138] K. M. Tharp, K. Kersten, O. Maller, et al., “Tumor-associated Macrophages Restrict CD8(+) T Cell Function Through Collagen Deposition and Metabolic Reprogramming of the Breast Cancer Microenvironment,” Nat Cancer 5, no. 7 (2024): 1045-1062.

[139] S. Meza-Perez, M. Liu, A. Silva-Sanchez, et al., “Proteobacteria Impair Anti-tumor Immunity in the Omentum by Consuming Arginine,” Cell Host & Microbe 32, no. 7 (2024): 1177-1191.e7.

[140] Z. Zou, Q. Cheng, J. Zhou, et al., “ATF4-SLC7A11-GSH Axis Mediates the Acquisition of Immunosuppressive Properties by Activated CD4(+) T Cells in Low Arginine Condition,” Cell reports 43, no. 4 (2024): 113995.

[141] H. Zhang, X. Zhu, T. J. Friesen, et al., “Annexin A2/TLR2/MYD88 Pathway Induces Arginase 1 Expression in Tumor-associated Neutrophils,” Journal of Clinical Investigation 132, no. 22 (2022): e153643.

[142] F. Wu, J. Yang, J. Liu, et al., “Signaling Pathways in Cancer-associated Fibroblasts and Targeted Therapy for Cancer,” Signal Transduct Target Ther 6, no. 1 (2021): 218.

[143] F. Sotgia, U. E. Martinez-Outschoorn, S. Pavlides, A. Howell, R. G. Pestell, and M. P. Lisanti, “Understanding the Warburg Effect and the Prognostic Value of Stromal Caveolin-1 as a Marker of a Lethal Tumor Microenvironment,” Breast Cancer Research 13, no. 4 (2011): 213.

[144] Z. Ou, L. Zhu, X. Chen, et al., “Hypoxia-Induced Senescent Fibroblasts Secrete IGF1 to Promote Cancer Stemness in Esophageal Squamous Cell Carcinoma,” Cancer Research 85, no. 6 (2025): 1064-1081.

[145] J. Bai, T. Liu, B. Tu, et al., “Autophagy Loss Impedes Cancer-associated Fibroblast Activation via Downregulating Proline Biosynthesis,” Autophagy 19, no. 2 (2023): 632-643.

[146] X. Zhong, X. He, Y. Wang, et al., “Warburg Effect in Colorectal Cancer: The Emerging Roles in Tumor Microenvironment and Therapeutic Implications,” Journal of hematology & oncology 15, no. 1 (2022): 160.

[147] B. Feng, J. Wu, B. Shen, F. Jiang, and J. Feng, “Cancer-associated Fibroblasts and Resistance to Anticancer Therapies: Status, Mechanisms, and Countermeasures,” Cancer cell international 22, no. 1 (2022): 166.

[148] A. Sakamoto, S. Kunou, K. Shimada, et al., “Pyruvate Secreted From Patient-derived Cancer-associated Fibroblasts Supports Survival of Primary Lymphoma Cells,” Cancer Science 110, no. 1 (2019): 269-278.

[149] Z. Wang, Y. Tan, W. Yu, et al., “Small Role With Big Impact: MiRNAs as Communicators in the Cross-talk Between Cancer-associated Fibroblasts and Cancer Cells,” Int J Biol Sci 13, no. 3 (2017): 339-348.

[150] Z. Gu, Y. Du, X. Zhao, and C. Wang, “Tumor Microenvironment and Metabolic Remodeling in Gemcitabine-based Chemoresistance of Pancreatic Cancer,” Cancer Letters 521 (2021): 98-108.

[151] U. E. Martinez-Outschoorn, M. P. Lisanti, and F. Sotgia, “Catabolic Cancer-associated Fibroblasts Transfer Energy and Biomass to Anabolic Cancer Cells, Fueling Tumor Growth,” Seminars in Cancer Biology 25 (2014): 47-60.

[152] M. Yang, B. Wang, W. Hou, et al., “NAD(+) Metabolism Enzyme NNMT in Cancer-associated Fibroblasts Drives Tumor Progression and Resistance to Immunotherapy by Modulating Macrophages in Urothelial Bladder Cancer,” Journal for ImmunoTherapy of Cancer 12, no. 7 (2024): e009281.

[153] W. Wang, I. Kryczek, L. Dostál, et al., “Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer,” Cell 165, no. 5 (2016): 1092-1105.

[154] M. Cummings, C. Freer, and N. M. Orsi, “Targeting the Tumour Microenvironment in Platinum-resistant Ovarian Cancer,” Seminars in Cancer Biology 77 (2021): 3-28.

[155] H. Zhang, H. Jiang, L. Zhu, J. Li, and S. Ma, “Cancer-associated Fibroblasts in Non-small Cell Lung Cancer: Recent Advances and Future Perspectives,” Cancer Letters 514 (2021): 38-47.

[156] J. Zhao, J. Shen, L. Mao, T. Yang, J. Liu, and S. Hongbin, “Cancer Associated Fibroblast Secreted miR-432-5p Targets CHAC1 to Inhibit Ferroptosis and Promote Acquired Chemoresistance in Prostate Cancer,” Oncogene 43, no. 27 (2024): 2104-2114.

[157] R. Qi, Y. Bai, K. Li, et al., “Cancer-associated Fibroblasts Suppress Ferroptosis and Induce Gemcitabine Resistance in Pancreatic Cancer Cells by Secreting Exosome-derived ACSL4-targeting miRNAs,” Drug Resistance Updates 68 (2023): 100960.

[158] K. Sun, X. Zhang, J. Shi, et al., “Elevated Protein Lactylation Promotes Immunosuppressive Microenvironment and Therapeutic Resistance in Pancreatic Ductal Adenocarcinoma,” Journal of Clinical Investigation 135, no. 7 (2025): e187024.

[159] M. Li, P. Sun, B. Tu, G. Deng, D. Li, and W. He, “Hypoxia Conduces the Glioma Progression by Inducing M2 Macrophage Polarization via Elevating TNFSF9 Level in a Histone-lactylation-dependent Manner,” American Journal of Physiology. Cell Physiology 327, no. 2 (2024): C487-c504.

[160] T. Lan, F. Gao, Y. Cai, et al., “The Protein circPETH-147aa Regulates Metabolic Reprogramming in Hepatocellular Carcinoma Cells to Remodel Immunosuppressive Microenvironment,” Nature Communications 16, no. 1 (2025): 333.

[161] Z. Zhong, K. Yang, Y. Li, et al., “Tumor-associated Macrophages Drive Glycolysis Through the IL-8/STAT3/GLUT3 Signaling Pathway in Pancreatic Cancer Progression,” Cancer Letters 588 (2024): 216784.

[162] H. Shen, O. A. Ojo, H. Ding, et al., “HIF1α-regulated Glycolysis Promotes Activation-induced Cell Death and IFN-γ Induction in Hypoxic T Cells,” Nature Communications 15, no. 1 ( 2024): 9394.

[163] G. J. Markowitz, Y. Ban, D. A. Tavarez, et al., “Deficiency of Metabolic Regulator PKM2 Activates the Pentose Phosphate Pathway and Generates TCF1(+) Progenitor CD8(+) T Cells to Improve Immunotherapy,” Nature Immunology 25, no. 10 (2024): 1884-1899.

[164] L. Wu, Y. Jin, and X. Zhao, “Tumor Aerobic Glycolysis Confers Immune Evasion Through Modulating Sensitivity to T Cell-mediated Bystander Killing via TNF-α,” Cell metabolism 35, no. 9 (2023): 1580-1596.e9.

[165] R. J. Kishton, M. Sukumar, and N. P. Restifo, “Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy,” Cell metabolism 26, no. 1 (2017): 94-109.

[166] P. S. Liu, Y. T. Chen, X. Li, et al., “CD40 signal Rewires Fatty Acid and Glutamine Metabolism for Stimulating Macrophage Anti-tumorigenic Functions,” Nature Immunology 24, no. 3 (2023): 452-462.

[167] X. Yang, B. Deng, W. Zhao, et al., “FABP5(+) lipid-loaded Macrophages Process Tumour-derived Unsaturated Fatty Acid Signal to Suppress T-cell Antitumour Immunity,” Journal of Hepatology 82, no. 4 (2025): 676-689.

[168] S. M. Hwang, D. Awasthi, J. Jeong, et al., “Transgelin 2 Guards T Cell Lipid Metabolism and Antitumour Function,” Nature 635, no. 8040 (2024): 1010-1018.

[169] W. Chen, J. M. N. Teo, S. W. Yau, et al., “Chronic Type I Interferon Signaling Promotes Lipid-peroxidation-driven Terminal CD8(+) T Cell Exhaustion and Curtails Anti-PD-1 Efficacy,” Cell reports 41, no. 7 (2022): 111647.

[170] E. G. Hunt, K. E. Hurst, B. P. Riesenberg, et al., “Acetyl-CoA Carboxylase Obstructs CD8(+) T Cell Lipid Utilization in the Tumor Microenvironment,” Cell metabolism 36, no. 5 (2024): 969-983.e10.

[171] F. Ma, X. Liu, Y. Zhang, et al., “Tumor Extracellular Vesicle-derived PD-L1 Promotes T Cell Senescence Through Lipid Metabolism Reprogramming,” Science Translational Medicine 17, no. 785 (2025): eadm7269.

[172] C. Uyttenhove, L. Pilotte, I. Théate, et al., “Evidence for a Tumoral Immune Resistance Mechanism Based on Tryptophan Degradation by Indoleamine 2,3-dioxygenase,” Nature Medicine 9, no. 10 (2003): 1269-1274.

[173] M. Solvay, P. Holfelder, S. Klaessens, et al., “Tryptophan Depletion Sensitizes the AHR Pathway by Increasing AHR Expression and GCN2/LAT1-mediated Kynurenine Uptake, and Potentiates Induction of Regulatory T Lymphocytes,” Journal for ImmunoTherapy of Cancer 11, no. 6 (2023): e006728.

[174] R. Qin, C. Zhao, C. J. Wang, et al., “Tryptophan Potentiates CD8(+) T Cells Against Cancer Cells by TRIP12 Tryptophanylation and Surface PD-1 Downregulation,” Journal for ImmunoTherapy of Cancer 9, no. 7 (2021): e002840.

[175] J. C. N. Kenski, X. Huang, D. W. Vredevoogd, et al., “An Adverse Tumor-protective Effect of IDO1 Inhibition,” Cell Rep Med 4, no. 2 (2023): 100941.

[176] K. Hezaveh, R. S. Shinde, A. Klötgen, et al., “Tryptophan-derived Microbial Metabolites Activate the Aryl Hydrocarbon Receptor in Tumor-associated Macrophages to Suppress Anti-tumor Immunity,” Immunity 55, no. 2 (2022): 324-340.e8.

[177] J. Huang, X. Wang, B. Li, et al., “L-5-hydroxytryptophan Promotes Antitumor Immunity by Inhibiting PD-L1 Inducible Expression,” Journal for ImmunoTherapy of Cancer 10, no. 6 (2022): e003957.

[178] J. L. Wei, S. Y. Wu, Y. S. Yang, et al., “GCH1 induces Immunosuppression Through Metabolic Reprogramming and IDO1 Upregulation in Triple-negative Breast Cancer,” Journal for ImmunoTherapy of Cancer 9, no. 7 (2021): e002383.

[179] Y. Bian, W. Li, D. M. Kremer, et al., “Cancer SLC43A2 Alters T Cell Methionine Metabolism and Histone Methylation,” Nature 585, no. 7824 (2020): 277-282.

[180] L. Yang, Z. Chu, M. Liu, et al., “Amino Acid Metabolism in Immune Cells: Essential Regulators of the Effector Functions, and Promising Opportunities to Enhance Cancer Immunotherapy,” Journal of hematology & oncology 16, no. 1 (2023): 59.

[181] Z. Deng, F. Zhou, M. Li, et al., “DLGAP5 enhances Bladder Cancer Chemoresistance by Regulating Glycolysis Through MYC Stabilization,” Theranostics 15, no. 6 (2025): 2375-2392.

[182] D. He, M. Chen, L. Chang, et al., “De Novo Pyrimidine Synthesis Fuels Glycolysis and Confers Chemoresistance in Gastric Cancer,” Cancer Letters 549 (2022): 215837.

[183] Y. Zeng, H. Jiang, X. Zhang, et al., “Canagliflozin Reduces Chemoresistance in Hepatocellular Carcinoma Through PKM2-c-Myc Complex-mediated Glutamine Starvation,” Free Radic Biol Med 208 (2023): 571-586.

[184] C. C. Wong, J. Xu, X. Bian, et al., “In Colorectal Cancer Cells with Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance,” Gastroenterology 159, no. 6 (2020): 2163-2180.e6.

[185] K. Zhou, D. Wang, X. Du, X. Feng, X. Zhu, and C. Wang, “UBE2C enhances Temozolomide Resistance by Regulating the Expression of p53 to Induce Aerobic Glycolysis in Glioma,” Acta Biochim Biophys Sin (Shanghai) 56, no. 6 (2024): 916-926.

[186] Y. Chen, M. Xian, W. Ying, et al., “Succinate Dehydrogenase Deficiency-driven Succinate Accumulation Induces Drug Resistance in Acute Myeloid Leukemia via Ubiquitin-cullin Regulation,” Nature Communications 15, no. 1 (2024): 9820.

[187] X. Ge, M. Li, J. Yin, et al., “Fumarate Inhibits PTEN to Promote Tumorigenesis and Therapeutic Resistance of type2 Papillary Renal Cell Carcinoma,” Molecular Cell 82, no. 7 (2022): 1249-1260.e7.

[188] D. J. Zabransky, E. Kartalia, J. W. Lee, et al., “Tumor-derived CCL2 Drives Tumor Growth and Immunosuppression in IDH1- mutant Cholangiocarcinoma,” Hepatology (2024), https://doi.org/10.1097/hep.0000000000001185.

[189] W. Dai, L. Xu, X. Yu, et al., “OGDHL Silencing Promotes Hepatocellular Carcinoma by Reprogramming Glutamine Metabolism,” Journal of Hepatology 72, no. 5 (2020): 909-923.

[190] J. Dai, X. Lu, C. Zhang, et al., “NNMT Promotes Acquired EGFR-TKI Resistance by Forming EGR1 and Lactate-mediated Double Positive Feedback Loops in Non-small Cell Lung Cancer,” Molecular cancer 24, no. 1 (2025): 79.

[191] T. Zhang, Z. Pan, J. Gao, et al., “Branched-chain Amino Acid Transaminase 1 Confers EGFR-TKI Resistance Through Epigenetic Glycolytic Activation,” Signal Transduct Target Ther 9, no. 1 (2024): 216.

[192] N. Duan, Y. Hua, X. Yan, et al., “Unveiling Alterations of Epigenetic Modifications and Chromatin Architecture Leading to Lipid Metabolic Reprogramming During the Evolutionary Trastuzumab Adaptation of HER2-Positive Breast Cancer,” Adv Sci (Weinh) 11, no. 18 (2024): e2309424.

[193] C. Jiang, Y. Zhu, H. Chen, et al., “Targeting c-Jun Inhibits Fatty Acid Oxidation to Overcome Tamoxifen Resistance in Estrogen Receptor-positive Breast Cancer,” Cell death & disease 14, no. 10 (2023): 653.

[194] L. Bi, Y. Ren, M. Feng, et al., “HDAC11 Regulates Glycolysis Through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness,” Cancer Research 81, no. 8 (2021): 2015-2028.

[195] T. Ge, X. Gu, R. Jia, et al., “Crosstalk Between Metabolic Reprogramming and Epigenetics in Cancer: Updates on Mechanisms and Therapeutic Opportunities,” Cancer Commun (Lond) 42, no. 11 (2022): 1049-1082.

[196] C. Bergamini, I. Leoni, N. Rizzardi, et al., “MiR-494 Induces Metabolic Changes Through G6pc Targeting and Modulates Sorafenib Response in Hepatocellular Carcinoma,” Journal of Experimental & Clinical Cancer Research 42, no. 1 (2023): 145.

[197] Z. Song, G. Jia, P. Ma, and S. Cang, “Exosomal miR-4443 Promotes Cisplatin Resistance in Non-small Cell Lung Carcinoma by Regulating FSP1 m6A Modification-mediated Ferroptosis,” Life Sciences 276 (2021): 119399.

[198] Y. T. Tan, J. F. Lin, T. Li, J. J. Li, R. H. Xu, and H. Q. Ju, “LncRNA-mediated Posttranslational Modifications and Reprogramming of Energy Metabolism in Cancer,” Cancer Commun (Lond) 41, no. 2 (2021): 109-120.

[199] X. Chen, R. Luo, Y. Zhang, et al., “Long Noncoding RNA DIO3OS Induces Glycolytic-dominant Metabolic Reprogramming to Promote Aromatase Inhibitor Resistance in Breast Cancer,” Nature Communications 13, no. 1 (2022): 7160.

[200] X. Li, Y. Zhang, X. Wang, et al., “Long Non-coding RNA CTSLP8 Mediates Ovarian Cancer Progression and Chemotherapy Resistance by Modulating Cellular Glycolysis and Regulating c-Myc Expression Through PKM2,” Cell Biology and Toxicology 38, no. 6 (2022): 1027-1045.

[201] J. Ma, W. Zhao, H. Zhang, et al., “Long Non-coding RNA ANRIL Promotes Chemoresistance in Triple-negative Breast Cancer via Enhancing Aerobic Glycolysis,” Life Sciences 306 (2022): 120810.

[202] G. Gambi, G. Mengus, G. Davidson, et al., “The LncRNA LENOX Interacts With RAP2C to Regulate Metabolism and Promote Resistance to MAPK Inhibition in Melanoma,” Cancer Research 82, no. 24 (2022): 4555-4570.

[203] Y. Geng, X. Zheng, D. Zhang, et al., “CircHIF1A induces Cetuximab Resistance in Colorectal Cancer by Promoting HIF1α-mediated Glycometabolism Alteration,” Biology Direct 19, no. 1 (2024): 36.

[204] K. Luo, A. Liu, H. Wu, et al., “CircKIF4A promotes Glioma Growth and Temozolomide Resistance by Accelerating Glycolysis,” Cell death & disease 13, no. 8 (2022): 740.

[205] S. B. Patel, T. Nemkov, D. Stefanoni, et al., “Metabolic Alterations Mediated by STAT3 Promotes Drug Persistence in CML,” Leukemia 35, no. 12 (2021): 3371-3382.

[206] J. Li, Q. Xia, C. Di, et al., “Tumor Cell-Intrinsic CD96 Mediates Chemoresistance and Cancer Stemness by Regulating Mitochondrial Fatty Acid β-Oxidation,” Adv Sci (Weinh) 10, no. 7 (2023): e2202956.

[207] S. C. Di, W. J. Chen, W. Yang, et al., “DEPDC1 as a Metabolic Target Regulates Glycolysis in Renal Cell Carcinoma Through AKT/mTOR/HIF1α Pathway,” Cell death & disease 15, no. 7 (2024): 533.

[208] Y. Nan, X. Wu, Q. Luo, et al., “OTUB2 silencing Promotes Ovarian Cancer via Mitochondrial Metabolic Reprogramming and Can be Synthetically Targeted by CA9 Inhibition,” Pnas 121, no. 19 (2024): e2315348121.

[209] T. Shima, K. Taniguchi, Y. Tokumaru, et al., “Glucose Transporter‑1 Inhibition Overcomes Imatinib Resistance in Gastrointestinal Stromal Tumor Cells,” Oncology Reports 47, no. 1 (2022): 7.

[210] H. J. Jae, J. W. Chung, H. S. Park, et al., “The Antitumor Effect and Hepatotoxicity of a Hexokinase II Inhibitor 3-bromopyruvate: In Vivo Investigation of Intraarterial Administration in a Rabbit VX2 Hepatoma Model,” Korean Journal of Radiology 10, no. 6 (2009): 596-603.

[211] L. S. Ihrlund, E. Hernlund, O. Khan, and M. C. Shoshan, “3-Bromopyruvate as Inhibitor of Tumour Cell Energy Metabolism and Chemopotentiator of Platinum Drugs,” Mol Oncol 2, no. 1 (2008): 94-101.

[212] X. Hu, X. Peng, Y. Zhang, et al., “Shikonin Reverses Cancer-associated Fibroblast-induced Gemcitabine Resistance in Pancreatic Cancer Cells by Suppressing Monocarboxylate Transporter 4-mediated Reverse Warburg Effect,” Phytomedicine 123 (2024): 155214.

[213] M. Manerba, L. Di Ianni, L. Fiume, M. Roberti, M. Recanatini, and G. Di Stefano, “Lactate Dehydrogenase Inhibitors Sensitize Lymphoma Cells to Cisplatin Without Enhancing the Drug Effects on Immortalized Normal Lymphocytes,” European Journal of Pharmaceutical Sciences 74 (2015): 95-102.

[214] Z. Zhang, R. Liu, Y. Shuai, et al., “ASCT2 (SLC1A5)-dependent Glutamine Uptake Is Involved in the Progression of Head and Neck Squamous Cell Carcinoma,” British Journal of Cancer 122, no. 1 (2020): 82-93.

[215] J. K. Byun, M. Park, S. Lee, et al., “Inhibition of Glutamine Utilization Synergizes With Immune Checkpoint Inhibitor to Promote Antitumor Immunity,” Molecular Cell 80, no. 4 (2020): 592-606.e8.

[216] M. Praharaj, F. Shen, A. J. Lee, et al., “Metabolic Reprogramming of Tumor-Associated Macrophages Using Glutamine Antagonist JHU083 Drives Tumor Immunity in Myeloid-Rich Prostate and Bladder Cancers,” Cancer immunology research 12, no. 7 (2024): 854-875.

[217] A. Frejlachova, R. Lencova, A. Venhauerova, et al., “The Combination of Immunotherapy and a Glutamine Metabolism Inhibitor Represents an Effective Therapeutic Strategy for Advanced and Metastatic Murine Pancreatic Adenocarcinoma,” International Immunopharmacology 118 (2023): 110150.

[218] J. Encarnación-Rosado, A. S. W. Sohn, D. E. Biancur, et al., “Targeting Pancreatic Cancer Metabolic Dependencies Through Glutamine Antagonism,” Nat Cancer (2023), https://doi.org/10.1038/s43018-023-00647-3.

[219] J. E. Hernandez-Davies, T. Q. Tran, M. A. Reid, et al., “Vemurafenib Resistance Reprograms Melanoma Cells towards Glutamine Dependence,” Journal of translational medicine 13 (2015): 210.

[220] R. Pillai, S. E. LeBoeuf, Y. Hao, et al., “Glutamine Antagonist DRP-104 Suppresses Tumor Growth and Enhances Response to Checkpoint Blockade in KEAP1 Mutant Lung Cancer,” Science Advances 10, no. 13 (2024): eadm9859.

[221] Z. E. Stine, Z. T. Schug, J. M. Salvino, and C. V. Dang, “Targeting Cancer Metabolism in the Era of Precision Oncology,” Nat Rev Drug Discovery 21, no. 2 (2022): 141-162.

[222] Y. Zhao, X. Feng, Y. Chen, et al., “5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 Against PIK3CA-Mutant Colorectal Cancers,” Cancer Research 80, no. 21 (2020): 4815-4827.

[223] K. K. Ciombor, S. W. Bae, J. G. Whisenant, et al., “Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal Cancer,” Clinical Cancer Research 31, no. 8 (2025): 1437-1448.

[224] D. O. Bauerschlag, N. Maass, P. Leonhardt, et al., “Fatty Acid Synthase Overexpression: Target for Therapy and Reversal of Chemoresistance in Ovarian Cancer,” Journal of translational medicine 13 (2015): 146.

[225] J. J. Souchek, A. Laliwala, L. Houser, L. Muraskin, Q. Vu, and A. M. Mohs, “Fatty Acid Synthase Inhibitors Enhance Microtubule-Stabilizing and Microtubule-Destabilizing Drugs in Taxane-Resistant Prostate Cancer Cells,” ACS Pharmacol Transl Sci 6, no. 12 (2023): 1859-1869.

[226] G. Falchook, J. Infante, H. T. Arkenau, et al., “First-in-human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of First-in-class Fatty Acid Synthase Inhibitor TVB-2640 Alone and With a Taxane in Advanced Tumors,” EClinicalMedicine 34 (2021): 100797.

[227] L. Zhou, K. Du, Y. Dai, et al., “Metabolic Reprogramming Based on RNA Sequencing of Gemcitabine-resistant Cells Reveals the FASN Gene as a Therapeutic for Bladder Cancer,” Journal of translational medicine 22, no. 1 (2024): 55.

[228] J. Huang, W. Y. Tsang, X. N. Fang, et al., “FASN Inhibition Decreases MHC-I Degradation and Synergizes With PD-L1 Checkpoint Blockade in Hepatocellular Carcinoma,” Cancer Research 84, no. 6 (2024): 855-871.

[229] W. Kelly, A. E. Diaz Duque, J. Michalek, et al., “Phase II Investigation of TVB-2640 (Denifanstat) With Bevacizumab in Patients With First Relapse High-Grade Astrocytoma,” Clinical Cancer Research 29, no. 13 (2023): 2419-2425.

[230] J. K. Shim, S. Choi, S. J. Yoon, et al., “Etomoxir, a Carnitine Palmitoyltransferase 1 Inhibitor, Combined With Temozolomide Reduces Stemness and Invasiveness in Patient-derived Glioblastoma Tumorspheres,” Cancer cell international 22, no. 1 (2022): 309.

[231] F. Chen, S. Wu, N. Kuang, Y. Zeng, M. Li, and C. Xu, “ABCB1-mediated Docetaxel Resistance Reversed by Erastin in Prostate Cancer,” Febs Journal 291, no. 14 (2024): 3249-3266.

[232] H. Feng, J. Yu, Z. Xu, et al., “SLC7A9 suppression Increases Chemosensitivity by Inducing Ferroptosis via the Inhibition of Cystine Transport in Gastric Cancer,” EBioMedicine 109 (2024): 105375.

[233] N. Sharma, A. Bhushan, J. He, G. Kaushal, and V. Bhardwaj, “Metabolic Plasticity Imparts Erlotinib-resistance in Pancreatic Cancer by Upregulating Glucose-6-phosphate Dehydrogenase,” Cancer Metab 8 (2020): 19.

[234] L. Wei, D. Lee, C. T. Law, et al., “Genome-wide CRISPR/Cas9 Library Screening Identified PHGDH as a Critical Driver for Sorafenib Resistance in HCC,” Nature Communications 10, no. 1 (2019): 4681.

[235] S. Elsaadi, I. Steiro, P. Abdollahi, et al., “Targeting Phosphoglycerate Dehydrogenase in Multiple Myeloma,” Exp Hematol Oncol 10, no. 1 (2021): 3.

[236] X. Wu, J. Xia, J. Zhang, et al., “Phosphoglycerate Dehydrogenase Promotes Proliferation and Bortezomib Resistance Through Increasing Reduced Glutathione Synthesis in Multiple Myeloma,” British Journal of Haematology 190, no. 1 (2020): 52-66.

[237] J. K. Dong, H. M. Lei, Q. Liang, et al., “Overcoming Erlotinib Resistance in EGFR Mutation-positive Lung Adenocarcinomas Through Repression of Phosphoglycerate Dehydrogenase,” Theranostics 8, no. 7 (2018): 1808-1823.

[238] Z. Lin, J. Li, J. Zhang, et al., “Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer,” Cancer Research 83, no. 13 (2023): 2187-2207.

[239] K. W. Evans, E. Yuca, S. S. Scott, et al., “Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer,” Cancer Research 81, no. 21 (2021): 5572-5581.

[240] R. El-Botty, L. Morriset, E. Montaudon, et al., “Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy and Palbociclib Resistant Metastatic Breast Cancers,” Nature Communications 14, no. 1 (2023): 4221.

[241] N. Zhang, L. Sun, S. Zhou, et al., “Cholangiocarcinoma PDHA1 Succinylation Suppresses Macrophage Antigen Presentation via Alpha-ketoglutaric Acid Accumulation,” Nature Communications 16, no. 1 (2025): 3177.

[242] C. Arnold, P. Demuth, N. Seiwert, et al., “The Mitochondrial Disruptor Devimistat (CPI-613) Synergizes With Genotoxic Anticancer Drugs in Colorectal Cancer Therapy in a Bim-Dependent Manner,” Molecular Cancer Therapeutics 21, no. 1 (2022): 100-112.

[243] R. Anderson, L. D. Miller, S. Isom, et al., “Phase II Trial of Cytarabine and Mitoxantrone With Devimistat in Acute Myeloid Leukemia,” Nature Communications 13, no. 1 (2022): 1673.

[244] P. A. Philip, V. Sahai, N. Bahary, et al., “Devimistat (CPI-613) with Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) versus FFX for Patients with Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study,” Journal of Clinical Oncology 42, no. 31 (2024): 3692-3701.

[245] Y. C. Shen, D. L. Ou, C. Hsu, et al., “Activating Oxidative Phosphorylation by a Pyruvate Dehydrogenase Kinase Inhibitor Overcomes Sorafenib Resistance of Hepatocellular Carcinoma,” British Journal of Cancer 108, no. 1 (2013): 72-81.

[246] Y. Liu, Y. Cao, W. Zhang, et al., “A Small-molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-cycle Arrest, and Inhibits Cancer Cell Growth in Vitro and in Vivo,” Molecular Cancer Therapeutics 11, no. 8 (2012): 1672-1682.

[247] H. Huang, F. L. Kung, Y. W. Huang, C. C. Hsu, J. H. Guh, and L. C. Hsu, “Sensitization of Cancer Cells to Paclitaxel-induced Apoptosis by canagliflozin,” Biochemical Pharmacology 223 (2024): 116140.

[248] X. Chen, Y. Zhao, C. He, et al., “Identification of a Novel GLUT1 Inhibitor With in Vitro and in Vivo Anti-tumor Activity,” International Journal of Biological Macromolecules 216 (2022): 768-778.

[249] M. Mu, Q. Zhang, C. Zhao, et al., “3-Bromopyruvate Overcomes Cetuximab Resistance in human Colorectal Cancer Cells by Inducing Autophagy-dependent Ferroptosis,” Cancer Gene Therapy 30, no. 10 (2023): 1414-1425.

[250] S. K. Gandham, M. Talekar, A. Singh, and M. M. Amiji, “Inhibition of Hexokinase-2 With Targeted Liposomal 3-bromopyruvate in an Ovarian Tumor Spheroid Model of Aerobic Glycolysis,” Int J Nanomedicine 10 (2015): 4405-4423.

[251] B. Zhao, A. Aggarwal, J. A. Marshall, et al., “Glycolytic Inhibition With 3-bromopyruvate Suppresses Tumor Growth and Improves Survival in a Murine Model of Anaplastic Thyroid Cancer,” Surgery 171, no. 1 (2022): 227-234.

[252] Z. Zeng, J. Lan, S. Lei, et al., “Simultaneous Inhibition of Ornithine Decarboxylase 1 and Pyruvate Kinase M2 Exerts Synergistic Effects against Hepatocellular Carcinoma Cells,” Onco Targets Ther 13 (2020): 11697-11709.

[253] K. Urbańska and A. Orzechowski, “Unappreciated Role of LDHA and LDHB to Control Apoptosis and Autophagy in Tumor Cells,” International Journal of Molecular Sciences 20, no. 9 (2019): 2085.

[254] M. Manerba, M. Vettraino, L. Fiume, et al., “Galloflavin (CAS 568-80-9): A Novel Inhibitor of Lactate Dehydrogenase,” Chemmedchem 7, no. 2 (2012): 311-317.

[255] Z. Ma, J. Yang, W. Jia, et al., “Histone Lactylation-driven B7-H3 Expression Promotes Tumor Immune Evasion,” Theranostics 15, no. 6 (2025): 2338-2359.

[256] D. N. Edwards, V. M. Ngwa, A. L. Raybuck, et al., “Selective Glutamine Metabolism Inhibition in Tumor Cells Improves Antitumor T Lymphocyte Activity in Triple-negative Breast Cancer,” Journal of Clinical Investigation 131, no. 4 (2021): e140100.

[257] Z. Luo, J. Xu, J. Sun, et al., “Co-delivery of 2-Deoxyglucose and a Glutamine Metabolism Inhibitor V9302 via a Prodrug Micellar Formulation for Synergistic Targeting of Metabolism in Cancer,” Acta Biomaterialia 105 (2020): 239-252.

[258] G. Ma, H. Jia, Z. Li, et al., “Gefitinib Reverses PD-L1-Mediated Immunosuppression Induced by Long-term Glutamine Blockade in Bladder Cancer,” Cancer immunology research 13, no. 1 (2025): 66-83.

[259] R. Rais, K. M. Lemberg, L. Tenora, et al., “Discovery of DRP-104, a Tumor-targeted Metabolic Inhibitor Prodrug,” Science Advances 8, no. 46 (2022): eabq5925.

[260] Y. Yokoyama, T. M. Estok, and W. R. Sirpiglenastat, “(DRP-104) Induces Antitumor Efficacy Through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems,” Molecular Cancer Therapeutics 21, no. 10 (2022): 1561-1572.

[261] N. Y. Jeong, J. S. Lee, K. S. Yoo, et al., “Fatty Acid Synthase Inhibitor Cerulenin Inhibits Topoisomerase I Catalytic Activity and Augments SN-38-induced Apoptosis,” Apoptosis 18, no. 2 (2013): 226-237.

[262] I. Nandi, L. Ji, and H. W. Smith, “Targeting Fatty Acid Oxidation Enhances Response to HER2-targeted Therapy,” Nature Communications 15, no. 1 (2024): 6587.

[263] K. Wang, L. Luo, S. Fu, et al., “PHGDH Arginine Methylation by PRMT1 Promotes Serine Synthesis and Represents a Therapeutic Vulnerability in Hepatocellular Carcinoma,” Nature Communications 14, no. 1 (2023): 1011.

[264] J. M. Rohde, K. R. Brimacombe, L. Liu, et al., “Discovery and Optimization of Piperazine-1-thiourea-based human Phosphoglycerate Dehydrogenase Inhibitors,” Bioorganic & Medicinal Chemistry 26, no. 8 (2018): 1727-1739.

[265] J. R. Molina, Y. Sun, M. Protopopova, et al., “An Inhibitor of Oxidative Phosphorylation Exploits Cancer Vulnerability,” Nature Medicine 24, no. 7 (2018): 1036-1046.

[266] T. A. Yap, N. Daver, M. Mahendra, et al., “Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials,” Nature Medicine 29, no. 1 (2023): 115-126.

[267] K. Vasan, M. Werner, and N. S. Chandel, “Mitochondrial Metabolism as a Target for Cancer Therapy,” Cell metabolism 32, no. 3 (2020): 341-352.

[268] L. Lang, F. Wang, Z. Ding, et al., “Blockade of Glutamine-dependent Cell Survival Augments Antitumor Efficacy of CPI-613 in Head and Neck Cancer,” Journal of Experimental & Clinical Cancer Research 40, no. 1 (2021): 393.

[269] M. O. James, S. C. Jahn, G. Zhong, M. G. Smeltz, Z. Hu, and P. W. Stacpoole, “Therapeutic Applications of Dichloroacetate and the Role of Glutathione Transferase Zeta-1,” Pharmacology & Therapeutics 170 (2017): 166-180.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.